Serum Fatty Acids and Risk of Cutaneous Melanoma: A Population-Based Case-Control Study

Table 2

Fatty acid plasma percentage distribution in study subjects.

Systematic name	Common name	Short designation	Cases		Controls
			Min	Max	Min	Max	33th centile^a	67th centile^a
SFAs^b
Hexadecanoic	Palmitic	(16  :  0)	27.70	42.75	26.35	42.75	35.10	36.92
Heptadecanoic	Margaric (daturic)	(17 : 0)	0.19	3.20	0.01	4.97	0.52	0.64
Octadecanoic	Stearic	(18 : 0)	11.84	22.41	8.52	21.89	16.53	18.10
Eicosanoic	Arachidic	(20 : 0)	0.01	1.11	0.01	1.26	0.32	0.47
Tetracosanoic	Lignoceric	(24 : 0)	0.01	2.25	0.01	1.65	0.72	1.11
MUFAs^b
cis-9-octadecenoic	Oleic	(18 : 1n-9)	9.52	41.69	8.21	38.47	12.72	14.88
cis-15-tetracosenoic	Nervonic	(24 : 1n-9)	0.01	4.02	0.01	3.52	1.04	1.62
PUFAs^b
9,12-octadecadienoic	Linoleic	(18 : 2n-6)	11.34	23.56	11.32	23.54	17.19	20.07
5,8,11,14-eicosatetraenoic	Arachidonic	(20 : 4n-6)	0.28	7.41	1.08	6.77	2.75	3.77
5,8,11,14,17-eicosapentaenoic	EPA	(20 : 5n-3)	0.01	1.44	0.01	2.35	0.14	0.33
7,10,13,16,19-docosapentaenoic	DPA	(22 : 5n-3)	0.01	0.60	0.01	0.75	0.09	0.18
4,7,10,13,16,19-docosahexaenoic	DHA	(22 : 6n-3)	0.18	2.06	0.01	1.95	0.43	0.66
			Mean	Standard deviation	Mean	Standard deviation	33th centile^a	66th centile^a
Groupings
SFAs			55.95	3.59	55.68	4.12	54.57	56.72
MUFAs + PUFAs			39.29	3.86	39.37	4.18	38.34	40.73
MUFAs			16.27	5.02	16.22	4.99	14.31	16.52
PUFAs			23.02	4.59	23.15	3.60	21.58	25.06
SFAs/MUFAs + PUFAs			1.44	0.21	1.44	0.26	1.35	1.48
SFAs/PUFAs			2.54	0.58	2.47	0.47	2.23	2.61
n-3 PUFAs			1.10	0.60	1.06	0.69	0.71	1.11
n-6 PUFAs			21.92	4.33	22.09	3.40	20.53	24.04
n-3 PUFAs/n-6 PUFAs			0.05	0.02	0.05	0.03	0.03	0.05

^aPercentile cutpoints based on fatty acid distribution in controls.
^bSFAs: saturated fatty acids; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acids.